Clinical Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
07/11/2013
07/11/2013
2012
|
Resumo |
Purpose: To report the clinical outcome of the treatment of dry eyes using 0.03% tacrolimus eye drops (olive oil + tacrolimus 0.03%) (Ophthalmos, Sao Paulo, Brazil). Methods: Sixteen eyes of 8 patients with Sjogren syndrome dry eyes (age, 51.13 +/- 9.45 years) were enrolled in this study (prospective noncontrolled interventional case series). Patients were instructed to use topical 0.03% tacrolimus eye drops twice a day (every 12 hours) in the lower conjunctival sac. Schirmer I test, break-up time, corneal fluorescein, and rose bengal staining score were performed in all patients 1 day before, and 14, 28, and 90 days after treatment with 0.03% tacrolimus eye drops. Results: The average fluorescein staining and rose bengal staining scores improved statistically significantly after 14 days of treatment and improved even more after 28 and 90 days. The average Schirmer I test did not improve statistically significantly after 28 days of treatment, although we did observe a significant improvement after 90 days of treatment with 0.03% tacrolimus eye drops. The average break-up time did not improve statistically after 14 days of treatment, although we observed a significant improvement after 28 and 90 days of treatment with 0.03% tacrolimus eye drops. Conclusions: Topical 0.03% tacrolimus eye drops successfully improved tear stability and ocular surface status in patients with dry eyes. |
Identificador |
CORNEA, PHILADELPHIA, v. 31, n. 8, p. 945-949, AUG, 2012 0277-3740 http://www.producao.usp.br/handle/BDPI/43181 10.1097/ICO.0b013e31823f8c9b |
Idioma(s) |
eng |
Publicador |
LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA |
Relação |
CORNEA |
Direitos |
closedAccess Copyright LIPPINCOTT WILLIAMS & WILKINS |
Palavras-Chave | #DRY EYE SYNDROME #SJOGREN SYNDROME #KERATOCONJUNCTIVIS SICCA #CORNEA #TACROLIMUS #FK506 #REPEATED OCULAR INSTILLATION #VERSUS-HOST-DISEASE #T-CELL ACTIVATION #ATOPIC-DERMATITIS #KERATOCONJUNCTIVITIS SICCA #ALLERGIC CONJUNCTIVITIS #TOPICAL FK506 #WORKSHOP 2007 #IMMUNOSUPPRESSIVE AGENT #FK-506 #OPHTHALMOLOGY |
Tipo |
article original article publishedVersion |